GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Modus Therapeutics Holding MODTX.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.17

+6.25%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Modus Therapeutics Holding

Its shares trade on Nasdaq Stockholm under the ticker MODTX.ST. It has been listed since 22 July 2021.

Modus Therapeutics Holding AB operates as a biotechnology company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-07-22. The firm's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Jul 2021
Website
modustx.com ↗

Leadership

Pay as last reported

  • Dr. Viktor DrvotaChairman of the Board, since 2016
  • Dr. John OhdChief Executive Officer
  • Mr. Claes LindbladChief Financial Officer
  • Ms. Ellen DonnellyIndependent Board Member

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Stockholm, Sweden
  • Focus on developing sevuparin for sepsis treatment
  • Sevuparin has a patented multimodal mechanism of action

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • Limited focus on a single drug candidate
  • Biotechnology sector with inherent development risks

Opportunities

  • Potential market for sepsis treatment with high unmet need
  • Sevuparin's reduced bleeding risk compared to heparinoids
  • IPO in 2021 provides capital for development

Threats

  • Biotechnology development risks including clinical trial failures
  • Competition in the sepsis treatment market
  • Regulatory hurdles for drug approval

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.